• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Two Pharma Stocks Enjoying Good Health

These large-cap companies have topped expectations for four quarters and are projected to again report robust earnings.
By KATE STALTER Oct 13, 2012 | 09:00 AM EDT
Stocks quotes in this article: ALXN, VRX

A stock I've written about numerous times here is Alexion Pharmaceuticals (ALXN). I have no sentimental attachment to it, nor do I particularly care what the "story" is. You could say that I'm not returning to the stock now, but that it's returning to me -- in the form of showing up again and again on my top-performing large-cap scans.

Alexion, which makes treatments for autoimmune disorders, transplant rejection conditions, cancer and various other ailments, is set to report its third quarter on Oct. 18 before the open. Wall Street has pegged earnings at $0.47 per share, up 27% from the year-earlier quarter.

Revenue is expected to come in at $293.19 million, a year-over-year gain of 31%. The company has notched double-digit revenue and earnings increases during every quarter of the past two years. Free cash flow per share has been on the rise since it moved into positive territory in 2008, and return on equity is solid at 27%.

Alexion beat earnings estimates in each of the past four quarters.

The company has market capitalization of about $21.5 billion, and the stock trades about 974,000 shares per day on average. That volume is a bit on the low side for the market cap, given that the stock has gained institutional owners as it has rallied higher.

As for the chart, the shares have gotten a bit frothy, although they pulled back this week along with the broader market. The stock rallied to an all-time high of $119.54 on Oct. 5. In this week's retreat, Alexion has gotten support just above its key 50-day moving average. The last time it dipped below that line for any extended time was in April, May and June. A consolidation of several weeks could be constructive at this point. Of course, next week's earnings report could serve as a catalyst for a price move in either direction.

Another good performer from the ranks of large-cap pharmaceuticals is Valeant (VRX). Valeant makes drugs to treat nervous system ailments and cardiovascular diseases.

The company's market cap is $17 billion. It trades nearly 1.7 million shares per day, on average.

Unlike Alexion, which has trended above its 10-week line for months, Valeant has traded in fits and starts. For months it hit resistance below $60, and was unable to gain enough traction for a bigger rally.

Th stock cleared that price hurdle last month, but quickly receded. On Friday, Valeant was holding 3% above its 50-day line, and about 8.5% below its Sept. 7 high of $61.11.

Volume has been trending lower recently amid consolidation in the stock That's not a bad sign; increased volume on a pullback could signal heavy selling, or churn -- active trading without upward price progress.

Valeant is scheduled to report its third quarter on Oct. 31 before the open. It is seen delivering a treat, not a trick, with per-share income estimated at $1.08 per share, a year-over-year increase of 64%.

As with Alexion, Valeant topped earnings views in each of the past four quarters.

Earlier this week, Stifel Nicolaus reiterated its Buy rating on Valeant, and upped its price target to $75 from $60.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stalter had no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Walgreens Boots Alliance Rallies Ahead of Earnings

Bruce Kamich
Jan 27, 2021 2:45 PM EST

Has WBA rallied too much?

2 More Covered Call Opportunities That Are Calling Investors

Bret Jensen
Jan 25, 2021 8:30 AM EST

Here are options plays involving promising small-caps Clearside Biomedical and Mustang Bio.

Trade Carefully With Soaring Gritstone Oncology

Bruce Kamich
Jan 21, 2021 8:16 AM EST

The history we are concerned about is the past couple of weeks.

UnitedHealth Group Charts Appear Toppy Ahead of Earnings

Bruce Kamich
Jan 19, 2021 8:53 AM EST

The technical indicators of the health benefits concern are not sending strong signals at present.

Moderna Now Looks Like an Effective Long Trade With Few Side Effects

Bruce Kamich
Jan 14, 2021 12:06 PM EST

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:48 AM EST STEPHEN GUILFOYLE

    Cashing in Some More Chips at Stocks Under $10

    We're trimming a position for a big gain today.
  • 08:34 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/27/2021

    The "correction" can be coming sooner than we thou...
  • 09:35 AM EST CHRIS VERSACE

    Another Big Winner for Stocks Under $10

    We're ringing the register Tuesday morning.
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login